NCT/Study#
NCT02339571 /
EA6141
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase II/III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
